Quantcast

Latest Circassia Ltd Stories

2009-05-13 04:00:00

OXFORD, England, May 13 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated a phase II clinical development programme for its ragweed allergy therapy. The treatment for allergic rhino-conjunctivitis caused by ragweed pollen is based on Circassia's ToleroMune(R) technology, which has previously achieved successful phase II results in patients with cat allergies. Ragweed is one of the leading causes of allergic...

2009-04-21 04:00:00

OXFORD, England, April 21 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced today that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma. The lastest study, which is underway in...

2008-10-08 06:00:34

OXFORD, England, October 8 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international speciality pharmaceutical company Ipsen. Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product....

2008-10-02 06:00:34

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous phase II clinical trial,...

2008-09-10 06:00:08

OXFORD, England, September 10 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients. Circassia conducted...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related